Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $269.32 Consensus Target Price from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Free Report) has earned an average recommendation of “Moderate Buy” from the twenty-four brokerages that are covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $269.32.

ALNY has been the topic of several recent analyst reports. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. SVB Leerink increased their price target on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group lifted their price objective on shares of Alnylam Pharmaceuticals from $174.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research report on Wednesday, July 3rd.

Read Our Latest Analysis on ALNY

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at $35,632. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,848 shares of company stock worth $24,683,444. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $30,000. Robeco Institutional Asset Management B.V. lifted its position in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the period. Finally, GAMMA Investing LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $262.89 on Thursday. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $274.93. The company has a market cap of $33.25 billion, a P/E ratio of -98.09 and a beta of 0.37. The stock’s 50-day simple moving average is $227.65 and its 200 day simple moving average is $179.08.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.21) EPS. As a group, equities analysts predict that Alnylam Pharmaceuticals will post -3.99 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

(Get Free Report

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.